Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).

Abstract

BACKGROUND Boosted protease inhibitor (bPI) monotherapy (bPImono) potentially has substantial cost, safety and operational benefits. It has never been evaluated as second-line antiretroviral therapy (ART) in Africa. METHODS After 24 weeks of lopinavir/ritonavir-containing second-line therapy, DART participants were randomized to remain on combination… (More)
DOI: 10.3851/IMP2253